⌘K
Loading ticker…
Alnylam Pharmaceuticals, Inc. · Healthcare · Pharmaceutical Products
As of 2026-06-26, Alnylam Pharmaceuticals, Inc. (ALNY) has a 3-month relative strength percentile of 24 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 42. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 3.5%, relative volume 1.16×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
24 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
ALNY is in a stage 4 downtrend, week 9. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -1.8% / -21.3%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
ALNY is held by 13 ETFs as of Mar 2026. Top owner: VTI at 0.07% weight, $1.4B notional. Top 3 carry $3.3B.
Top 10 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.07% | $1.4B |
| VOVanguard Mid-Cap ETF | 0.48% | $948M |
| QQQInvesco QQQ Trust Series I | 0.25% | $924M |
| VUGVanguard Growth ETF | 0.16% | $518M |
| VXFVanguard Extended Market ETF | 0.60% | $490M |
| VOTVanguard Mid-Cap Growth ETF | 1.14% | $334M |
| IWFiShares Russell 1000 Growth ETF | 0.15% | $169M |
| IWRiShares Russell Midcap ETF | 0.33% | $160M |
| JEPQJPMorgan NASDAQ Equity Premium Income ETF | 0.29% | $98M |
| XBIState Street SPDR S&P Biotech ETF | 1.18% | $87M |
Showing 10 of 13 ETF owners.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALNY Jan avg: -3.52% median: -7.20% win: 25% σ: 13.23% n: 4 2022-04-12 → 2026-05-29 | ALNY Feb avg: -9.66% median: -10.84% win: 0% σ: 6.02% n: 4 2022-04-12 → 2026-05-29 | ALNY Mar avg: 3.09% median: 2.01% win: 50% σ: 4.96% n: 4 2022-04-12 → 2026-05-29 | ALNY Apr avg: -5.69% median: -3.68% win: 0% σ: 5.75% n: 5 2022-04-12 → 2026-05-29 | ALNY May avg: 0.71% median: -2.43% win: 40% σ: 9.26% n: 5 2022-04-12 → 2026-05-29 | ALNY Jun avg: 22.35% median: 11.50% win: 100% σ: 28.13% n: 4 2022-04-12 → 2026-05-29 (current) | ALNY Jul avg: 4.57% median: 0.30% win: 50% σ: 10.78% n: 4 2022-04-12 → 2026-05-29 | ALNY Aug avg: 17.80% median: 12.23% win: 100% σ: 19.23% n: 4 2022-04-12 → 2026-05-29 | ALNY Sep avg: -1.70% median: -0.51% win: 50% σ: 6.70% n: 4 2022-04-12 → 2026-05-29 | ALNY Oct avg: -3.45% median: -1.53% win: 50% σ: 7.71% n: 4 2022-04-12 → 2026-05-29 | ALNY Nov avg: 2.79% median: 2.69% win: 50% σ: 7.18% n: 4 2022-04-12 → 2026-05-29 | ALNY Dec avg: 0.65% median: 0.36% win: 50% σ: 12.08% n: 4 2022-04-12 → 2026-05-29 |